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Abstract: Companion animals are now living longer and so are more 
commonly manifesting age- and pain-related disease. Nonsteroidal anti-
inflammatory drugs are the most used drug in osteoarthritis and 
inflammatory pain of various aetiologies. Despite their safety profiles 
have been amended from the COX-non selective to the COX-2 selective 
inhibitor class, some adverse effects are still of concern especially in 
long term treatments. One prostaglandin (PG) downstream from the 
cyclooxygenase enzyme, PGE2, has been recognized as a pivotal 
mediator of pain and inflammation. The actions of PGE2 are produced by 
its interaction with four G-protein coupled receptors (EP1, EP2, EP3 and 
EP4). The EP4 receptor mediates PGE2-elicited sensitization of sensory 
neurons and studies have demonstrated that EP4 is a major receptor in 
mediating pain associated with both rheumatoid and osteoarthritis and in 
inflammation. CJ-023,423 (grapiprant) is a competitive antagonist of human 
and rat prostanoid EP4 receptors, under development for the control of pain 
and inflammation associated with osteoarthritisfor use in humans and dogs. A 
recent study has shown the good safety profile of this active ingredient in 
dogs. Despite this molecule is still far to be marketed because it 
pharmacokinetic/pharmacodynamics profile is need to be fully elucidated yet, 
it might be an interesting active ingredient for the veterinary medicine. 
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Introduction 
Companion animals are now living longer and so are 
more commonly manifesting age-related diseases of 
medical importance such as cancer, arthritis and 
metabolic disorders. They also share other life style, 
similarities that make them more suitable animal models 
than many of the traditionally used laboratory animals 
that can have drug resistance profiles that are quite 
different to those in humans (Giorgi, 2012). Most if not 
all these diseases are pain and inflammation associated. 
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and 
selective Cyclooxygenase (COX)-2 inhibitors are 
mainstays of the pharmacopoeia for the treatment of 
signs and symptoms of osteoarthritis and inflammatory 
pain of various etiologies. 
Their mechanism of action is to decrease 
prostaglandin (PG) synthesis by inhibiting COX 
activities. Two isoforms of COX, COX-1 and COX-2, 
have been identified. COX-1 is constitutively expressed 
throughout the body and it is thought to play an essential 
role in normal gastrointestinal and renal function, 
whereas COX-2 is induced in the presence of 
inflammation. NSAIDs inhibit both isoforms and 
inhibition of COX-1 is thought to cause the adverse 
gastrointestinal effects such as gastric erosion, ulceration 
and haemorrhage, whereas inhibition of COX-2 is 
associated with the therapeutic effects of NSAIDs. Thus, 
inhibition of PG synthesis by NSAIDs has demonstrated 
clear efficacy in the reduction of pain and inflammation 
and also has been shown to have putative effects beyond 
pain, including gastrointestinal and renal effects. These 
effects have been shown to be more severe in several 
animal species rather than in human beings (Khan and 
McLean, 2012). Selective COX-2 inhibitors were 
designed to prevent those adverse effects mediated by 
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inhibition of COX-1 (Zhang et al., 1997; Hinz and Brune, 
2002), but prolonged use of COX-2-selective inhibitors 
may, as with NSAIDs, confer a risk of cardiovascular 
events, including hypertension, edema, heart attack and 
stroke (Graham et al., 2005; Lenzer, 2005; Solomon et al., 
2005). The cause of the adverse cardiovascular effects 
remains unclear, but it may include an imbalance in 
prostacyclin and thromboxane levels in the 
endothelium (Bing and Lomnicka, 2002) and blockade 
of prostanoid actions on renal function (Nasrallah and 
Hebert, 2005). Despite the COX-2 selective inhibitors 
of second generation have displayed reduced 
cardiovascular effects and so far they have never been 
reported in animal species, they still remain a concern 
for long lasting therapies (Kim and Giorgi, 2013). 
Identification of new therapeutic targets downstream 
of COX may provide an opportunity for the development 
of new analgesics that interfere with prostanoid 
proinflammatory and pronociceptive actions with less 
gastrointestinal, renal and cardiovascular risk. 
One PG downstream from the cyclooxygenase 
enzyme, PGE2, has long been recognized as a pivotal 
mediator of pain and inflammation (Dannhardt and 
Kiefer, 2001). The pathological and homeostatic effects 
of PGE2 are mediated via a family of G protein-coupled 
receptor subtypes, designated EP1–4 (Fig. 1). These 
receptor subtypes are distinguished by their distinct 
pattern of tissue distribution, signaling pathways and 
physiological functions (Coleman et al., 1994). EP1 is 
coupled to intracellular Ca
2+
 mobilization, EP2 and EP4 
are coupled to stimulation of adenylate cyclase via Gs 
protein and EP3 is coupled to inhibition of adenylate 
cyclase via Gi protein. Studies performed either in mutant 
mice lacking the individual PG receptors (Stock et al., 
2001) or with synthetic EP receptor agonist/antagonist 
(Nakayama et al., 2002) have not yet provided a coherent 
picture of which EP receptors are responsible for 
inflammatory pain. Recently it has been reported that EP4 
knockdown with intrathecally delivered short hairpin RNA 
attenuates inflammation-induced thermal and mechanical 
behavioral hypersensitivity (Lin et al., 2006), suggesting 
that EP4 is a potential target for the pharmacological 
treatment of inflammatory pain. However, developing 
subtype-selective EP receptor antagonists has been 
difficult because of the existence of multiple PG receptor 
subtypes and the lack of the selectivity of synthetic PG 
analogs. Thus, defining the contribution of EP receptor 
subtype to pain sensitization on the basis of available 
antagonists remains elusive. Nowadays, pets are treated 
as members of the family and pet owners demand the 
same level of care they expect for themselves. This 
change in attitude has resulted in a push for the 
development of more effective and innovative veterinary 
therapies (Giorgi, 2012; Giorgi and Owen, 2012a; 
2012b; Giorgi and Yun, 2012; Lee et al., 2014).
 
 
 
Fig. 1. Phospholipids cascade process involved in inflammation. Target points where diverse drugs can act are indicated 
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Is hence critical that the research in veterinary 
pharmacology is aimed to find out new active 
ingredients with good safety profile and efficacy. 
One of the new promising molecules that has been 
testing with this purpose is the CJ-023,423 (N-[({2-[4-
(2-ethyl-4,6-dimethyl-1H-imidazo [4, 5-c] pyridin-1-yl) 
phenyl] ethyl}amino) carbonyl]-4-methylbenzen 
esulfonamide), a novel, potent and selective EP4 
antagonist (Nakao et al., 2007). 
CJ-023,423 (also named grapiprant) is highly 
selective for the human EP4 receptor compared with 
other human prostanoid receptors (i.e., EP1, EP2, EP3, 
prostaglandin D, F and I receptors and tromboxan A 
receptor). Grapiprant was discovered in 2007 and it 
showed a competitive antagonist of human and rat 
prostanoid EP4 receptors with similar potency (pA2 = 
8.3±0.03 and 8.2±0.2 nM, respectively). In addition it 
was at least 200 times more selective over other human 
prostanoid receptors. The in vivo pharmacological 
antagonism of EP4 receptor with grapiprant produces 
antihyperalgesic effects in rat models of inflammatory 
pain, suggesting that inflammatory pain can be treated by 
targeting a single PG receptor subtype EP4 (Nakao et al., 
2007). Orally administrated CJ-023,423 reduced 
inflammatory pain such as carrageenan-induced 
mechanical hyperalgesia and CFA-induced weight-
bearing deficit in rats. Grapiprant is now under 
development for use in humans and dogs for the control 
of pain and inflammation associated with osteoarthritis. 
Most of data are protected but recently a short abstract 
has shown the good safety profile of this active 
ingredient in dogs. Treatment with grapiprant was well-
tolerated when given at doses up to 50 mg kg
−1 
for 9 
months to Beagle dogs (Rausch-Derra and Rhodes, 
2014). Treatment was associated with mild 
gastrointestinal signs and with mild and reversible 
decreases in serum total protein and albumin overtime, 
with incidence increasing as dose increased. Even with 
the high dose and long duration of this study, no 
treatment effects on liver or kidney function, or gross or 
his to pathological findings of the liver, kidney, or 
stomach, or on coagulation parameters were reported. 
The relative lack of toxic effects with grapiprant 
compared to those seen with non-steroidal anti-
inflammatory drugs working via the inhibition of the 
cyclooxygenase enzymes was expected. Indeed 
grapiprant, which shows selective antagonism of the EP4 
receptor, does not interfere with the production of 
prostanoids and therefore will not affect the other 
prostanoid receptor pathways, as occurs with 
cyclooxygenase inhibitor drugs. 
Targets downstream of COX inhibition, such as 
selective EP4 antagonism, might therefore provide an 
opportunity for the development of more specific and better 
tolerated analgesics beyond COX inhibition. Further studies 
are now needed to investigate the pharmacokinetic and 
pharmacodynamics profile in the target species. 
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